Bridging The FDA/EMA Drug Approvals Gap
This article was originally published in SRA
Pharmaceutical companies still tend to seek new drug approvals from the US Food and Drug Administration before applying for marketing authorization in the EU, but this could change as a result of initiatives like the European Medicines Agency's PRIME (priority medicines) and its parallel scientific advice procedure with health technology assessment bodies, according to a new report from regulatory consultancy NDA Group1.
You may also be interested in...
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.
As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks.
The new EU commissioner for health has been given a number of high-priority tasks, including medicines supply and tackling antimicrobial resistance. These topics will be taken up by the European Commission’s advisory body, the Pharmaceutical Committee, in its new work plan.